RU2756506C2 - Галогензамещенное гетероциклическое соединение - Google Patents

Галогензамещенное гетероциклическое соединение Download PDF

Info

Publication number
RU2756506C2
RU2756506C2 RU2018109925A RU2018109925A RU2756506C2 RU 2756506 C2 RU2756506 C2 RU 2756506C2 RU 2018109925 A RU2018109925 A RU 2018109925A RU 2018109925 A RU2018109925 A RU 2018109925A RU 2756506 C2 RU2756506 C2 RU 2756506C2
Authority
RU
Russia
Prior art keywords
thiophen
amino
carbonyl
biphenyl
ethoxy
Prior art date
Application number
RU2018109925A
Other languages
English (en)
Russian (ru)
Other versions
RU2018109925A (ru
RU2018109925A3 (enExample
Inventor
Нориаки ИВАСЕ
Хироси НИСИДА
Макото ОКУДО
Масааки ИТО
Сигеюки КОНО
Масааки МАТОЯМА
Сигеру УСИЯМА
Эйдзи ОКАНАРИ
Хирофуми МАЦУНАГА
Кендзи НИСИКАВА
Томио Кимура
Original Assignee
Убе Индастриз, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Убе Индастриз, Лтд. filed Critical Убе Индастриз, Лтд.
Publication of RU2018109925A publication Critical patent/RU2018109925A/ru
Publication of RU2018109925A3 publication Critical patent/RU2018109925A3/ru
Application granted granted Critical
Publication of RU2756506C2 publication Critical patent/RU2756506C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/36Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
RU2018109925A 2012-12-28 2013-12-27 Галогензамещенное гетероциклическое соединение RU2756506C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2012286425 2012-12-28
JP2012-286425 2012-12-28
JP2013097171 2013-05-02
JP2013-097171 2013-05-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015131139A Division RU2649398C2 (ru) 2012-12-28 2013-12-27 Галогензамещенное гетероциклическое соединение

Publications (3)

Publication Number Publication Date
RU2018109925A RU2018109925A (ru) 2019-02-27
RU2018109925A3 RU2018109925A3 (enExample) 2020-12-03
RU2756506C2 true RU2756506C2 (ru) 2021-10-01

Family

ID=51021433

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018109925A RU2756506C2 (ru) 2012-12-28 2013-12-27 Галогензамещенное гетероциклическое соединение
RU2015131139A RU2649398C2 (ru) 2012-12-28 2013-12-27 Галогензамещенное гетероциклическое соединение

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015131139A RU2649398C2 (ru) 2012-12-28 2013-12-27 Галогензамещенное гетероциклическое соединение

Country Status (13)

Country Link
US (2) US10000463B2 (enExample)
EP (2) EP2940013B1 (enExample)
JP (3) JP6176258B2 (enExample)
KR (1) KR102189166B1 (enExample)
CN (2) CN107698555B (enExample)
AU (1) AU2013366898B2 (enExample)
BR (1) BR112015015275B1 (enExample)
CA (1) CA2896701C (enExample)
DK (2) DK2940013T3 (enExample)
ES (2) ES2667798T3 (enExample)
MX (1) MX369801B (enExample)
RU (2) RU2756506C2 (enExample)
WO (1) WO2014104372A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107698555B (zh) * 2012-12-28 2020-05-05 宇部兴产株式会社 卤素取代杂环化合物
CN105142635B (zh) 2013-03-15 2021-07-27 艾匹根生物技术有限公司 有用于治疗疾病的杂环化合物
JP2014231508A (ja) * 2013-05-02 2014-12-11 宇部興産株式会社 ハロゲン置換へテロ環化合物
CN106458964B (zh) * 2014-06-27 2019-11-22 宇部兴产株式会社 卤素取代杂环化合物的盐
KR20180082564A (ko) * 2015-11-20 2018-07-18 우베 고산 가부시키가이샤 Nash의 치료 또는 예방을 위한 의약 조성물
KR20220039718A (ko) * 2019-07-30 2022-03-29 다이쇼 세이야꾸 가부시끼가이샤 Lpa1 수용체를 길항하는 우레아 화합물
CN114728168B (zh) 2019-11-15 2024-04-09 吉利德科学公司 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途
TWI843503B (zh) 2020-06-03 2024-05-21 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
EP4161936A1 (en) 2020-06-03 2023-04-12 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
CN111909170B (zh) * 2020-09-11 2022-08-12 吉林奥来德光电材料股份有限公司 一种有机电致发光化合物、其制备方法以及包含该有机电致发光化合物的有机电致发光器件
EP4337641A1 (en) 2021-05-11 2024-03-20 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
JP7691522B2 (ja) 2021-05-13 2025-06-11 ギリアード サイエンシーズ, インコーポレイテッド Lpa受容体アンタゴニスト及びそれらの使用
EP4444707A1 (en) 2021-12-08 2024-10-16 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
CA3222642A1 (en) 2022-12-12 2024-06-12 Bmic Llc Downstream uses for briquettes and other forms of powder from asphalt shingle waste

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1258484A1 (en) * 2000-02-18 2002-11-20 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs
US20060194850A1 (en) * 2003-08-05 2006-08-31 Ajinomoto Co. Inc Novel azole compound
EA201100691A1 (ru) * 2008-12-15 2012-02-28 Амира Фармасьютикалс, Инк. Антагонисты рецепторов лизофосфатидной кислоты
WO2012078593A2 (en) * 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
WO2012138797A1 (en) * 2011-04-05 2012-10-11 Amira Pharmaceuticals, Inc. 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234318D1 (de) 2001-02-08 2009-12-24 Ono Pharmaceutical Co Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors
EA020742B1 (ru) 2008-09-29 2015-01-30 Эли Лилли Энд Компани Селективный модулятор рецепторов эстрогена
GB2470833B (en) 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
EP2462128B1 (en) 2009-08-04 2016-09-21 Amira Pharmaceuticals, Inc. Compounds as lysophosphatidic acid receptor antagonists
GB2474120B (en) 2009-10-01 2011-12-21 Amira Pharmaceuticals Inc Compounds as Lysophosphatidic acid receptor antagonists
GB2474748B (en) 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011091167A2 (en) 2010-01-22 2011-07-28 The General Hospital Corporation Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases
WO2011159632A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists for the treatment of conditions or diseases of the eye
WO2011159633A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
WO2011159635A1 (en) 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist for the treatment of dermal conditions
CN107721940A (zh) 2010-12-07 2018-02-23 阿米拉制药公司 多环lpa1拮抗剂及其使用
CA2844982A1 (en) 2011-08-15 2013-02-21 Intermune, Inc. Lysophosphatidic acid receptor antagonists
CN107698555B (zh) * 2012-12-28 2020-05-05 宇部兴产株式会社 卤素取代杂环化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1258484A1 (en) * 2000-02-18 2002-11-20 Kirin Beer Kabushiki Kaisha Novel isoxazole and thiazole compounds and use thereof as drugs
US20060194850A1 (en) * 2003-08-05 2006-08-31 Ajinomoto Co. Inc Novel azole compound
EA201100691A1 (ru) * 2008-12-15 2012-02-28 Амира Фармасьютикалс, Инк. Антагонисты рецепторов лизофосфатидной кислоты
WO2012078593A2 (en) * 2010-12-07 2012-06-14 Amira Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonists and uses thereof
WO2012138797A1 (en) * 2011-04-05 2012-10-11 Amira Pharmaceuticals, Inc. 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors

Also Published As

Publication number Publication date
MX2015008479A (es) 2015-09-23
KR102189166B1 (ko) 2020-12-09
BR112015015275A8 (pt) 2019-10-22
JP6176258B2 (ja) 2017-08-09
CN107698555A (zh) 2018-02-16
AU2013366898B2 (en) 2017-06-29
KR20150100756A (ko) 2015-09-02
CN104884447A (zh) 2015-09-02
RU2018109925A (ru) 2019-02-27
JP2017214410A (ja) 2017-12-07
EP3360869A1 (en) 2018-08-15
US20180258062A1 (en) 2018-09-13
DK3360869T3 (da) 2020-10-12
MX369801B (es) 2019-11-21
BR112015015275A2 (pt) 2017-07-11
EP2940013A1 (en) 2015-11-04
RU2018109925A3 (enExample) 2020-12-03
CN107698555B (zh) 2020-05-05
JP2019014739A (ja) 2019-01-31
JP6569792B2 (ja) 2019-09-04
EP2940013B1 (en) 2018-02-21
JP6414286B2 (ja) 2018-10-31
CA2896701A1 (en) 2014-07-03
US10597375B2 (en) 2020-03-24
BR112015015275B1 (pt) 2021-12-14
WO2014104372A1 (ja) 2014-07-03
RU2649398C2 (ru) 2018-04-03
AU2013366898A1 (en) 2015-08-13
JPWO2014104372A1 (ja) 2017-01-19
RU2015131139A (ru) 2017-02-03
CA2896701C (en) 2020-10-06
US20150376160A1 (en) 2015-12-31
ES2825031T3 (es) 2021-05-14
US10000463B2 (en) 2018-06-19
ES2667798T3 (es) 2018-05-14
CN104884447B (zh) 2017-10-10
DK2940013T3 (en) 2018-03-26
EP2940013A4 (en) 2016-08-03
EP3360869B1 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
RU2756506C2 (ru) Галогензамещенное гетероциклическое соединение
US9382197B2 (en) Substituted hydroxamic acids and uses thereof
US8034832B2 (en) Gyrase inhibitors and uses thereof
US10150728B2 (en) Alkylene derivatives
US20100278733A1 (en) Composition for diagnosis of amyloid-related disease
RU2641895C2 (ru) ГЕТЕРОЦИКЛИЛЬНЫЕ ПИРИМИДИНОВЫЕ АНАЛОГИ В КАЧЕСТВЕ ИНГИБИТОРОВ Tук2
US20130310379A1 (en) Modulators of methyl modifying enzymes, compositions and uses thereof
EP3330256B1 (en) HETEROCYCLIC DERIVATIVE HAVING TrkA-INHIBITING ACTIVITY
US9499533B2 (en) Aromatic 5-membered heterocyclic derivative having TRPV4-Inhibiting activity
US8404852B2 (en) Gyrase inhibitors and uses thereof
US6670367B1 (en) Azinyloxy, and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use as mixed ETA/ETB endothelin receptor antagonists
US6440975B1 (en) Amino acid derivatives, the preparation and use thereof as endothelin antagonists
US20150246938A1 (en) Novel olefin derivative
US20250092056A1 (en) Uracil derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same
WO2023051261A1 (zh) 一种亚胺类化合物及其应用
US6448248B1 (en) Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists
EP4238960A1 (en) Amide derivative having antiviral activity
EP2113258A1 (en) Aurone derivative-containing composition for diagnosis
US20170253607A1 (en) Long-acting hiv protease inhibitor
US12528790B2 (en) Amide derivative having antiviral activity
HK1026417A (en) Heterocyclic carboxylic acid derivatives, the production and use thereof as endothelin receptor antagonists